• Je něco špatně v tomto záznamu ?

Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013-2022

M. Liptáková, M. Malý, H. Orlíková, M. Špačková, R. Limberková, J. Kynčl

. 2024 ; 63 (4) : 205-213. [pub] 20240923

Status neindexováno Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24017712

INTRODUCTION: Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. METHODS: The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. RESULTS: A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0-89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35-44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. CONCLUSIONS: Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24017712
003      
CZ-PrNML
005      
20241016081853.0
007      
ta
008      
241008s2024 pl f 000 0|eng||
009      
AR
024    7_
$a 10.2478/sjph-2024-0027 $2 doi
035    __
$a (PubMed)39319020
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Liptáková, Monika $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0009000588204239
245    10
$a Monitoring the Effect of Vaccination on Mumps Cases Complications in the Czech Republic - Surveillance Data 2013-2022 / $c M. Liptáková, M. Malý, H. Orlíková, M. Špačková, R. Limberková, J. Kynčl
520    9_
$a INTRODUCTION: Mumps data were analysed to assess the effect of vaccination on mumps complications and hospitalisation. METHODS: The mumps cases reported to the Czech nationwide surveillance system from 2013 to 2022 were analysed using logistic regression with an odds ratio (aOR) adjusted for age, sex, year of onset and administrative region to measure the association between vaccination and complications or hospitalisation. Adjusted vaccine effectiveness (aVE) was calculated: aVE=(1-aOR)x100. RESULTS: A total of 11,913 mumps cases were reported, of which 6,885 (58%) were male. The median age of the study participants was 16 (range: 0-89 years). No complications occurred in 91% of patients. Mumps orchitis occurred in 633 (9%) male cases. A total of 946 (8%) patients required hospitalisation. The highest proportion of complications and hospitalisations was in the age group 35-44 years. Two doses of vaccine reduced statistically significantly the risk of any complications and of hospitalisation compared with unvaccinated patients: aOR 0.48 (95% CI: 0.37, 0.62), aVE of 52% (95% CI: 38, 63); and aOR 0.43 (95% CI: 0.33, 0.56), aVE of 57% (95% CI: 44, 67), respectively. Two doses showed statistically significant aVE 50% (95% CI: 32, 64) against orchitis, and 59% (95% CI: 23, 79) against meningitis. Among the two-dose recipients, the proportion of complications increased gradually with the time from the second dose. CONCLUSIONS: Our findings demonstrated a protective effect of two-dose vaccination against mumps complications and hospitalisation for mumps. We recommend continuing routine childhood mumps vaccination and maintaining high MMR coverage in Czechia.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Malý, Marek $u National Institute of Public Health, Department of Biostatistics, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0009000164294023
700    1_
$a Orlíková, Hana $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $u Charles University, Third Faculty of Medicine, Department of Epidemiology and Biostatistics, Ruská 87, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0000000202463645
700    1_
$a Špačková, Michaela $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $u University of Defense, Military Faculty of Medicine, Třebešská 1575, 500 01 Hradec Králové, Czech Republic $1 https://orcid.org/0000000245571910 $7 xx0232062
700    1_
$a Limberková, Radomíra $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic
700    1_
$a Kynčl, Jan $u National Institute of Public Health, Centre for Epidemiology and Microbiology, Šrobárova 49/48, 100 00 Prague 10, Czech Republic $u Charles University, Third Faculty of Medicine, Department of Epidemiology and Biostatistics, Ruská 87, 100 00 Prague 10, Czech Republic $1 https://orcid.org/0000000208042729
773    0_
$w MED00190087 $t Zdravstveno varstvo $x 0351-0026 $g Roč. 63, č. 4 (2024), s. 205-213
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39319020 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081849 $b ABA008
999    __
$a ok $b bmc $g 2196352 $s 1229663
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 63 $c 4 $d 205-213 $e 20240923 $i 0351-0026 $m Zdravstveno varstvo $n Zdr Varst $x MED00190087
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...